[1]杨忠昆 朱勤 胡竹林.改良三壁眶减压术治疗重症甲状腺相关性眼病的疗效观察[J].眼科新进展,2012,32(9):000-841-843.

点击复制

改良三壁眶减压术治疗重症甲状腺相关性眼病的疗效观察

分享到：

相似文献/References:

[1]陆燕,黄媛媛,蔡季平,等. SB431542和TGF-β1对甲状腺相关性眼病患者眼眶成纤维细胞α-SMA及CTGF基因表达的影响[J].眼科新进展,2015,35(3):210.[doi:10.13389/j.cnki.rao.2015.0057]
　LU Yan,HUANG Yuan-Yuan,CAl Ji-Ping,et al. Effects of SB431542 and TGF-B1 0n a-SMA and CTGF gene expression in orbital fibroblast of patients with thyroid-associated ophthalmolopathy[J].Recent Advances in Ophthalmology,2015,35(9):210.[doi:10.13389/j.cnki.rao.2015.0057]
[2]何志伟,胡欣,陈国芳,等.抗氧化剂：治疗甲状腺相关性眼病的新选择[J].眼科新进展,2022,42(5):417.[doi:10.13389/j.cnki.rao.2022.0085]
　HE Zhiwei,HU Xin,CHEN Guofang,et al.Antioxidant: a new therapy for thyroid associated ophthalmopathy[J].Recent Advances in Ophthalmology,2022,42(9):417.[doi:10.13389/j.cnki.rao.2022.0085]
[3]张浩,赵婧,葛小宁,等.甲状腺相关性眼病的诊断性生物标志物研究进展[J].眼科新进展,2022,42(7):562.[doi:10.13389/j.cnki.rao.2022.0115]
　ZHANG Hao,ZHAO Jing,GE Xiaoning,et al.Research progress in diagnostic biomarkers for thyroid-associated ophthalmopathy[J].Recent Advances in Ophthalmology,2022,42(9):562.[doi:10.13389/j.cnki.rao.2022.0115]